Comparing Apellis Pharmaceuticals (NASDAQ:APLS) & Daré Bioscience (NASDAQ:DARE)

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) and Daré Bioscience (NASDAQ:DARE – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Earnings & Valuation

This table compares Apellis Pharmaceuticals and Daré Bioscience’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$75.42 million	137.21	-$652.17 million	($6.27)	-14.17
Daré Bioscience	$10.00 million	8.89	-$30.95 million	($0.36)	-2.86

Daré Bioscience has lower revenue, but higher earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Daré Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Apellis Pharmaceuticals and Daré Bioscience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	0	4	8	1	2.77
Daré Bioscience	0	0	4	0	3.00

Apellis Pharmaceuticals presently has a consensus target price of $90.93, indicating a potential upside of 2.33%. Daré Bioscience has a consensus target price of $7.00, indicating a potential upside of 579.61%. Given Daré Bioscience’s stronger consensus rating and higher probable upside, analysts plainly believe Daré Bioscience is more favorable than Apellis Pharmaceuticals.

Profitability

This table compares Apellis Pharmaceuticals and Daré Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	-652.50%	-225.82%	-76.46%
Daré Bioscience	N/A	-162.16%	-69.54%

Insider & Institutional Ownership

87.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 9.2% of Daré Bioscience shares are held by institutional investors. 7.5% of Apellis Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of Daré Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Apellis Pharmaceuticals has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Summary

Daré Bioscience beats Apellis Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Apellis Pharmaceuticals

(Get Rating)

Apellis Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

About Daré Bioscience

(Get Rating)

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women’s reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.